• Read more about Identification of myeloproliferative neoplasm drug agents via predictive simulation modeling: assessing responsiveness with micro-environment derived cytokines.

Previous studies have shown that the bone marrow micro-environment supports the myeloproliferative neoplasms (MPN) phenotype including via the production of cytokines that can induce resistance to frontline MPN therapies.

• Read more about Predicting Clinical outcomes in cancer patients based on novel computational biology method of mapping the cancer mutanome

Background: Despite three FDA approved standard of care (SOC) therapeutics, 60% of patients with myelodysplastic syndromes (MDS) fail to achieve hematologic improvement and nearly all patients die of refractory disease.